1. Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma
- Author
-
Daniel M, Geynisman, Ella X, Du, Xiaoran, Yang, Selvam R, Sendhil, Viviana Del, Tejo, Keith A, Betts, and Stephen, Huo
- Subjects
Cancer Research ,Nivolumab ,Cost of Illness ,Oncology ,Cost Savings ,Antineoplastic Combined Chemotherapy Protocols ,Sunitinib ,Humans ,General Medicine ,Carcinoma, Renal Cell ,Ipilimumab ,Drug Costs ,Kidney Neoplasms - Abstract
Aims: To assess grade 3/4 adverse events (AEs) and costs of first-line nivolumab plus ipilimumab versus sunitinib in advanced or metastatic renal cell carcinoma. Methods: Individual patient data from the all treated population in the CheckMate 214 trial (nivolumab plus ipilimumab, n = 547; sunitinib, n = 535) were used to calculate the number of AEs. AE unit costs were obtained from US 2017 Healthcare Cost and Utilization Project and inflated to 2020 values. Results: The proportion of patients experiencing grade 3/4 AEs decreased over time. Patients who received nivolumab plus ipilimumab had lower average per-patient all-cause grade 3/4 AE costs versus sunitinib (12-month: US$15,170 vs US$20,342; 42-month: US$19,096 vs US$27,473). Conclusion: Treatment with nivolumab plus ipilimumab was associated with lower grade 3/4 AE costs than sunitinib.
- Published
- 2022
- Full Text
- View/download PDF